mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021

Reduced COVID‐19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS‐CoV‐2 Delta (B.1.617.2) variant. Two‐dose VE against laboratory‐confirmed SARS‐CoV‐2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time‐varying vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Huong Q., McClure, David L., King, Jennifer P., Meece, Jennifer K., Pattinson, David, Neumann, Gabriele, Kawaoka, Yoshihiro, Rolfes, Melissa A., Belongia, Edward A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111813/
https://www.ncbi.nlm.nih.gov/pubmed/35178857
http://dx.doi.org/10.1111/irv.12970
_version_ 1784709307834564608
author McLean, Huong Q.
McClure, David L.
King, Jennifer P.
Meece, Jennifer K.
Pattinson, David
Neumann, Gabriele
Kawaoka, Yoshihiro
Rolfes, Melissa A.
Belongia, Edward A.
author_facet McLean, Huong Q.
McClure, David L.
King, Jennifer P.
Meece, Jennifer K.
Pattinson, David
Neumann, Gabriele
Kawaoka, Yoshihiro
Rolfes, Melissa A.
Belongia, Edward A.
author_sort McLean, Huong Q.
collection PubMed
description Reduced COVID‐19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS‐CoV‐2 Delta (B.1.617.2) variant. Two‐dose VE against laboratory‐confirmed SARS‐CoV‐2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time‐varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID‐19 vaccines overall, 65% for Moderna, and 50% for Pfizer‐BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID‐19 vaccines overall, 59% for Moderna, and 52% for Pfizer‐BioNTech.
format Online
Article
Text
id pubmed-9111813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91118132022-05-17 mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021 McLean, Huong Q. McClure, David L. King, Jennifer P. Meece, Jennifer K. Pattinson, David Neumann, Gabriele Kawaoka, Yoshihiro Rolfes, Melissa A. Belongia, Edward A. Influenza Other Respir Viruses Short Communications Reduced COVID‐19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS‐CoV‐2 Delta (B.1.617.2) variant. Two‐dose VE against laboratory‐confirmed SARS‐CoV‐2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time‐varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID‐19 vaccines overall, 65% for Moderna, and 50% for Pfizer‐BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID‐19 vaccines overall, 59% for Moderna, and 52% for Pfizer‐BioNTech. John Wiley and Sons Inc. 2022-02-18 2022-07 /pmc/articles/PMC9111813/ /pubmed/35178857 http://dx.doi.org/10.1111/irv.12970 Text en © 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
McLean, Huong Q.
McClure, David L.
King, Jennifer P.
Meece, Jennifer K.
Pattinson, David
Neumann, Gabriele
Kawaoka, Yoshihiro
Rolfes, Melissa A.
Belongia, Edward A.
mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title_full mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title_fullStr mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title_full_unstemmed mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title_short mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
title_sort mrna covid‐19 vaccine effectiveness against sars‐cov‐2 infection in a prospective community cohort, rural wisconsin, november 2020 to december 2021
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111813/
https://www.ncbi.nlm.nih.gov/pubmed/35178857
http://dx.doi.org/10.1111/irv.12970
work_keys_str_mv AT mcleanhuongq mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT mccluredavidl mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT kingjenniferp mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT meecejenniferk mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT pattinsondavid mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT neumanngabriele mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT kawaokayoshihiro mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT rolfesmelissaa mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021
AT belongiaedwarda mrnacovid19vaccineeffectivenessagainstsarscov2infectioninaprospectivecommunitycohortruralwisconsinnovember2020todecember2021

Ejemplares similares